Paperpal Prime Logo

Journal for ImmunoTherapy of Cancer : Impact Factor & More

eISSN: 2051-1426pISSN: 2051-1426
JournalOpen Access

Key Metrics

CiteScore
14.3
Eigenfactor
0.01 - 0.05
Impact Factor
10 - 15
Scite Index
0.90 5-Year SI
SJR
Q1Oncology
SNIP
2.23
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Journal for ImmunoTherapy of Cancer

Journal for ImmunoTherapy of Cancer Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher BMJ PUBLISHING GROUP
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2885
Publication Time18
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
Society/Institute/SponsorSociety for Immunotherapy of Cancer
FrequencyContinuous publication
Publication Start Year2013
Publisher URLVisit website
Website URLVisit website
Publication Details
Other chargesVisit website
PlagiarismVisit website
Publication Time 18
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY-NC, CC BY, CC BY-NC-ND
OA statementVisit website
View less

Planning to publish in Journal for ImmunoTherapy of Cancer ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Journal for ImmunoTherapy of Cancer

Metabolic inhibition of glutamate-cysteine ligase increases dendritic cell-mediated antitumor immunity in melanoma.
  • 30 Jun 2026
  • Journal for immunotherapy of cancer
DEA hypothesis: disinhibition, enhancing recognition, and alerting the host are the three pillars of effective cancer immunotherapy.
  • 29 Jun 2026
  • Journal for immunotherapy of cancer
Correction: CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell.
  • 29 Jun 2026
  • Journal for immunotherapy of cancer
Chemotherapeutic induction of cytosolic single-stranded DNA accumulation sensitizes triple-negative breast cancer to immunotherapy.
  • 29 Jun 2026
  • Journal for immunotherapy of cancer
Guarding epithelial integrity: origins of adaptive immunity and cancer immunosurveillance over time and space.
  • 29 Jun 2026
  • Journal for immunotherapy of cancer
Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancer.
  • 29 Jun 2026
  • Journal for immunotherapy of cancer
Metabolic inhibition of glutamate-cysteine ligase increases dendritic cell-mediated antitumor immunity in melanoma.
  • 30 Jun 2026
  • Journal for immunotherapy of cancer
DEA hypothesis: disinhibition, enhancing recognition, and alerting the host are the three pillars of effective cancer immunotherapy.
  • 29 Jun 2026
  • Journal for immunotherapy of cancer
Correction: CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell.
  • 29 Jun 2026
  • Journal for immunotherapy of cancer
Chemotherapeutic induction of cytosolic single-stranded DNA accumulation sensitizes triple-negative breast cancer to immunotherapy.
  • 29 Jun 2026
  • Journal for immunotherapy of cancer
Guarding epithelial integrity: origins of adaptive immunity and cancer immunosurveillance over time and space.
  • 29 Jun 2026
  • Journal for immunotherapy of cancer
Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancer.
  • 29 Jun 2026
  • Journal for immunotherapy of cancer

FAQs on Journal for ImmunoTherapy of Cancer